Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early PET choline evaluation of response in metastatic castration-resistant prostate cancer treated with abiraterone acetate
2013-003058-25Phase 4Active
- Sponsor
- CHU Grenoble Alpes
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abiraterone in prostate cancer (PCa), sponsored by CHU Grenoble Alpes. Primary endpoint: Early F-choline PET response at 6 weeks. Started Feb 2014; status: active.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-003058-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003058-25.